Company Overview and News
JG SUMMIT Holdings, Inc. is hiking its capital spending for 2018 as it aims to grow its petrochemical, airline, property, food and beverage, and banking businesses amid higher oil prices in the world market and the further depreciation of the peso.
JGSMY JGS RBNTF CEBUY UVRBY RBLAY CEBUF RLC RRETY URC CEB JGSHF UVRBF RRHI
PayMaya Philippines has partnered with the local government unit (LGU) of Muntinlupa to launch a card that the city’s residents can use to receive cash benefits and make cashless transactions.
RBNTF RRETY RRHI
Retail magnate Lucio Co-led Puregold Price Club Inc. is bowing out of the convenience store business three years after debuting into this highly competitive segment, choosing to focus on the battleground for supermarkets.
PSKXF RBNTF RRETY SEVN PHSXY PSE PHSVY RRHI
Ormoc board member Mesias Arevalo, Robinsons Land Corp. (RLC) president Frederick D. Go, RLC celebrity endorser Maja Salvador, RLC SVP/GM Arlene G. Magtibay, Robinsons Retail Holdings president Robina Gokongwei-Pe, Ormoc City Mayor Richard Gomez, Vice Mayor Toto Locsin Jr.
RLC RBNTF RRETY SYBJF RBLAY SECB RRHI
The local stock barometer pulled back to the 7,500 level on Wednesday, weighed down by local currency jitters and the downturn across US and regional markets.
SVTMF PSKXF RBNTF BDOUY AYAAY SM BDOUF BDO SMIVY ALGGY RRETY ALGGF PHSXY PSE AGI ALI AYAAF RRHI
GLOBE Telecom, Inc. digital payments unit Globe Fintech Innovations, Inc. (Mynt) has partnered with the Primer Group of Companies for customers to use GCash scan-to-pay feature in the latter’s stores nationwide.
GLO RBNTF RRETY GTMEY GTMEF GLOPP GLOPA RRHI
RUSTAN Commercial Corp. (RCC) will retain the ownership of the Rustan’s trademark and trade name in light of the Gokongwei group’s acquisition of the supermarket business previously owned by the Tantoco family.
DFIHY RBNTF RRETY DFILF RRHI
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...